Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Lee

Showing results (411-420 of 594) with videos related to

Pageof 60
Sort By:
Journal of the National Cancer Institute|April 5, 2018
Met Receptor Tyrosine Kinase and Chemoprevention of Oral CancerPierre Saintigny, William N William, Jean-Philippe Foy, et al.
Molecular Cancer Therapeutics|July 22, 2017
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung CancerKazuhiko Shien, Vassiliki A Papadimitrakopoulou, Dennis Ruder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2026
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug CombinationsJason K Sicklick, Daisuke Nishizaki, Hirotaka Miyashita, et al.
The American Journal of Pathology|June 19, 2016
Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical ActivityMarina Cardó-Vila, Serena Marchiò, Masanori Sato, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2022
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast CancerParijatham S Thomas, Anisha B Patel, J Jack Lee, et al.
The Oncologist|September 20, 2022
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck CancerFaye M Johnson, Filip Janku, Mohamed A Gouda, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Endocrinology|March 31, 2011
Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer developmentWoo-Young Kim, Mi-Jung Kim, Hojin Moon, et al.
Molecular Cancer Therapeutics|July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted TherapeuticsJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Lung Cancer|August 9, 2020
Female Gender Predicts Augmented Immune Infiltration in Lung AdenocarcinomaCarmen Behrens, Pedro Rocha, Edwin R Parra, et al.
Pageof 60

Showing results (411-420 of 594) with videos related to

Sort By:
Pageof 60
Journal of the National Cancer Institute|April 5, 2018
Met Receptor Tyrosine Kinase and Chemoprevention of Oral CancerPierre Saintigny, William N William, Jean-Philippe Foy, et al.
Molecular Cancer Therapeutics|July 22, 2017
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung CancerKazuhiko Shien, Vassiliki A Papadimitrakopoulou, Dennis Ruder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2026
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug CombinationsJason K Sicklick, Daisuke Nishizaki, Hirotaka Miyashita, et al.
The American Journal of Pathology|June 19, 2016
Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical ActivityMarina Cardó-Vila, Serena Marchiò, Masanori Sato, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2022
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast CancerParijatham S Thomas, Anisha B Patel, J Jack Lee, et al.
The Oncologist|September 20, 2022
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck CancerFaye M Johnson, Filip Janku, Mohamed A Gouda, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Endocrinology|March 31, 2011
Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer developmentWoo-Young Kim, Mi-Jung Kim, Hojin Moon, et al.
Molecular Cancer Therapeutics|July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted TherapeuticsJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Lung Cancer|August 9, 2020
Female Gender Predicts Augmented Immune Infiltration in Lung AdenocarcinomaCarmen Behrens, Pedro Rocha, Edwin R Parra, et al.
Pageof 60